A systematic review: advances therapies in canine and feline mast cell tumours from 2010 to 2021.

An abstract of the research paper presented to the Faculty of Veterinary Medicine, Universiti Malaysia Kelantan, in partial requirement for the course DVT 5436 – Research Project
Mast cell tumours (MCTs) are one of the common neoplasia reported in canine and feline species with unpredictable biological behaviour. This creates difficulty in selection of treatment protocols and greatly affecting the treatment outcomes. Therefore, this systematic review is conducted to reveal the knowledge gap to venture into new therapy, also to summarize the responses and outcomes of advanced therapy for mast cell tumours in canine and feline patients reported between the years 2010 to 2021. Thus, a total of 18,760 publications from 2010 to 2021 were extracted from two databases, Science Direct and PubMed using 24 sets of search phrases. A total of 33 studies have met the eligibility criteria after four sequential screenings according to inclusion and exclusion criteria. 97.0% of studies included discussed canine MCTs, whereas 3.0% discussed feline MCTs. Various new and modifications of therapies such combination therapeutic protocols and novel chemotherapeutics drugs such as Tigilanol Tiglate (TT) have been reviewed in this paper. All proposed and reported therapies appeared to be beneficial and efficient in managing mast cell tumours in canine and feline species.
Keywords: Mast cell tumour, canine, feline, novel, therapy